News & Views | Published:

Tracing cancer networks with phosphoproteomics

Nature Biotechnology volume 28, pages 10281029 (2010) | Download Citation

A mass-spectrometry approach for identifying downstream events in cancer signaling pathways may help to tailor therapies to individual patients.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Science 312, 1162–1165 (2006).

  2. 2.

    et al. Sci. Signal. 3, ra64 (2010).

  3. 3.

    et al. Sci. Transl. Med. 2, 43ra55 (2010).

  4. 4.

    , & J. Clin. Oncol. 28, 1075–1083 (2010).

  5. 5.

    Nat. Rev. Cancer 6, 729–734 (2006).

  6. 6.

    et al. PLoS Med. 5, e8 (2008).

  7. 7.

    et al. J. Clin. Invest. 118, 3065–3074 (2008).

  8. 8.

    et al. Cancer Cell 18, 39–51 (2010).

  9. 9.

    & Nature 441, 424–430 (2006).

  10. 10.

    Nat. Rev. Mol. Cell Biol. 7, 952–958 (2006).

  11. 11.

    Nature 452, 548–552 (2008).

  12. 12.

    et al. Sci. Transl. Med. 2, 48ra66 (2010).

  13. 13.

    et al. Proc. Natl. Acad. Sci. USA 104, 7564–7569 (2007).

Download references

Author information

Affiliations

  1. David B. Solit and Ingo K. Mellinghoff are in the Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

    • David B Solit
    •  & Ingo K Mellinghoff

Authors

  1. Search for David B Solit in:

  2. Search for Ingo K Mellinghoff in:

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to David B Solit or Ingo K Mellinghoff.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt1010-1028

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing